# Beijing Mabworks Biotech

Source: https://onco.cc/companies/beijing-mabworks-biotech/  
OnCo record `beijing-mabworks-biotech` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Beijing Mabworks Biotech is a Chinese developer in Beijing that sponsors 4 registered cancer trials of MBS314 and MBS303.

## Summary

Beijing Mabworks Biotech appears on ClinicalTrials.gov as the industry sponsor of 4 interventional cancer trials (phase 1/2, 3), testing MBS314, MBS303, Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide, lenalinomide in relapsed or refractory multiple myeloma, non-hodgkin's lymphoma, follicular lymphoma and marginal zone lymphoma. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Beijing Mabworks Biotech Co., Ltd.
- Tags: ctgov-sponsor; china; registry-only
- HQ: Beijing, China
- Type: biotech

## Sources

- ClinicalTrials.gov: trials sponsored by Beijing Mabworks Biotech: https://clinicaltrials.gov/search?spons=Beijing%20Mabworks%20Biotech

## Connected records

- trials: [A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL](https://onco.cc/trials/nct05806099/), [A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.](https://onco.cc/trials/nct06232096/), [MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma](https://onco.cc/trials/nct04834024/), [MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)](https://onco.cc/trials/nct04110301/)

---
JSON: https://onco.cc/api/v1/entities/beijing-mabworks-biotech.json